Metabolic Disease
-
YOLT-101
Read MoreFamilial Hypercholesterolemia (FH)PCSK9In vivo LNP
Trial ID: NCT06461702 (Other Study ID Numbers: FH-YOLT-101-1)
Trial ID: NCT06458010 (Other Study ID Numbers: FH-YOLT-101-001)
-
YOLT-102
Read MoreASCVDUndisclosedIn vivo LNP
-
YOLT-103
UndisclosedUndisclosedIn vivo LNP
Genetic Disease
-
YOLT-201
Read More
Read MoreTransthyretin Amyloidosis (ATTR)TTRIn vivo LNP
Trial ID: NCT06082050 (Other Study ID Numbers: YOLT-201_2023_IIT_01)
Trial ID: NCT06539208 (Other Study ID Numbers: YT-YOLT-201-101)
-
YOLT-202
Read MoreAlpha-1 Antitrypsin Deficiency (AATD)UndisclosedIn vivo LNP
-
YOLT-203
Read More
Read MorePrimary Hyperoxaluria (PH1)HAO1In vivo LNP
Trial ID: NCT06511349 (Other Study ID Numbers: PH1-YOLT-203-001)
-
YOLT-204
Read MoreUndisclosedUndisclosedIn vivo LNP
-
YOLT-205
Read More
Read MoreHAEUndisclosedIn vivo LNP
Infectious Disease
Metabolic Disease
-
Indication
Familial Hypercholesterolemia (FH)
-
Target Gene
PCSK9
-
Delivery
In vivo LNP
Trial ID: NCT06461702 (Other Study ID Numbers: FH-YOLT-101-1)
Trial ID: NCT06458010 (Other Study ID Numbers: FH-YOLT-101-001)
-
Indication
ASCVD
-
Target Gene
Undisclosed
-
Delivery
In vivo LNP
-
Indication
Undisclosed
-
Target Gene
Undisclosed
-
Delivery
In vivo LNP
Genetic Disease
-
Indication
Transthyretin Amyloidosis (ATTR)
-
Target Gene
TTR
-
Delivery
In vivo LNP
Trial ID: NCT06082050 (Other Study ID Numbers: YOLT-201_2023_IIT_01)
Trial ID: NCT06539208 (Other Study ID Numbers: YT-YOLT-201-101)
-
Indication
Alpha-1 Antitrypsin Deficiency (AATD)
-
Target Gene
Undisclosed
-
Delivery
In vivo LNP
-
Indication
Primary Hyperoxaluria (PH1)
-
Target Gene
HAO1
-
Delivery
In vivo LNP
Trial ID: NCT06511349 (Other Study ID Numbers: PH1-YOLT-203-001)
-
Indication
Undisclosed
-
Target Gene
Undisclosed
-
Delivery
In vivo LNP
-
Indication
HAE
-
Target Gene
Undisclosed
-
Delivery
In vivo LNP
Infectious Disease
-
Indication
Hepatitis B
-
Target Gene
Undisclosed
-
Delivery
In vivo LNP
-
Indication
Undisclosed
-
Target Gene
Undisclosed
-
Delivery
In vivo LNP
